Allogeneic hematopoietic cell transplantation is followed by humoral immunodeficiency. We evaluated whether antibody levels can be improved by recipient vaccination on day À1 and 50 and whether the levels can be further improved by donor vaccination on day À20. A total of 85 patients were randomized or assigned to one of the following strategies of immunization with Streptococcus pneumoniae polysaccharides, Haemophilus influenzae polysaccharide-protein conjugate, tetanus toxoid (protein recall antigen) and hepatitis B surface antigen (protein neo-antigen): (1) donor on day À20, recipient on days À1, þ 50 and þ 365 (D À20 R À1,50,365 ); (2) donor nil, recipient on days À1, þ 50 and þ 365 (D N R À1,50,365 ); or (3) donor nil, recipient on day þ 365 (D N R 365 ). For H. influenzae and tetanus, IgG levels after grafting were the highest in the D À20 R À1,50,365 patients, intermediate in the D N R À1,50,365 patients and the lowest in the D N R 365 patients. For S. pneumoniae and hepatitis B, antibody levels appeared to be similar in all three patient groups. The results suggest that for polysaccharide-protein conjugate antigens or protein recall antigens, recipient immunization on days À1 and 50 improves antibody levels and that donor vaccination on day À20 further improves the levels. In contrast, neither recipient immunization on days À1 and 50 nor donor immunization on day À20 appears to be efficacious for polysaccharide antigens and poorly immunogenic protein neo-antigens. 3-6 Antibody levels can be improved either by the administration of immunoglobulin or by vaccination. The administration of immunoglobulin may decrease the rates of some infections at the time of immunoglobulin administration, but may hamper reconstitution of antibody immunity and thus increase infection rates after the immunoglobulin has been discontinued. 6 The vaccination can improve pathogen-specific immunity both at the time of vaccination as well as years after vaccination. However, vaccination during the first year after transplantation leads to only minor increases in specific antibody levels. Moderate to marked increases in specific antibody levels during the first year after transplant were achieved when both the donor and the recipient were immunized 7-10 days before transplantation and the recipient was boosted at 3 and 6 months after transplantation. 7, 8 Presumably this happened because large numbers of antigen-specific lymphocytes were generated in the donors and because these lymphocytes (transferred with the graft) or their progeny proliferated and differentiated upon encounter with the antigen injected to the recipient 7-10 days before transplant and at 3 and 6 months after transplant.
tion, antibody levels
Immune deficiency follows allogeneic hematopoietic cell transplantation and lasts for more than 1 year.
1,2 Deficient antibody immunity predisposes transplant recipients to infections, primarily those due to Streptococcus pneumoniae or Haemophilus influenzae. [3] [4] [5] [6] Antibody levels can be improved either by the administration of immunoglobulin or by vaccination. The administration of immunoglobulin may decrease the rates of some infections at the time of immunoglobulin administration, but may hamper reconstitution of antibody immunity and thus increase infection rates after the immunoglobulin has been discontinued. 6 The vaccination can improve pathogen-specific immunity both at the time of vaccination as well as years after vaccination. However, vaccination during the first year after transplantation leads to only minor increases in specific antibody levels. Moderate to marked increases in specific antibody levels during the first year after transplant were achieved when both the donor and the recipient were immunized 7-10 days before transplantation and the recipient was boosted at 3 and 6 months after transplantation. 7, 8 Presumably this happened because large numbers of antigen-specific lymphocytes were generated in the donors and because these lymphocytes (transferred with the graft) or their progeny proliferated and differentiated upon encounter with the antigen injected to the recipient 7-10 days before transplant and at 3 and 6 months after transplant.
We set out to compare the following three vaccination strategies: (1) donor vaccination on day À20 (20 days before transplant) with recipient vaccination on days À1, þ 50 and þ 365 (D À20 R À1,50,365 ); (2) no donor vaccination and recipient vaccination on days À1, þ 50 and þ 365 (D N R À1, 50, 365 ) and (3) a conventional strategy of no donor vaccination and recipient vaccination only late post transplant (on day þ 365, D N R 365 ) as presently recommended. 9 The rationale for immunizing the donors on day À20 instead of days À10 to À7 was to allow for the generation of an even greater number of antigen-specific lymphocytes to be transferred with the graft. 10 The rationale for immunizing the recipient on day -1 instead of days À10 to À7 was to maximize the boosting effect of the antigen as theoretically a significant fraction of the antigen administered on days À10 to À7 could be metabolized or eliminated by the day of transplant (day 0). Only one early post transplant booster (on day 50 instead of at both 3 and 6 months) was given for practicality, as our patients typically return to the referring physician around 3 months and return to us for evaluation only at 1 year post transplant. The reason for comparing the D N R À1,50,365 strategy with the D N R 365 strategy was to evaluate the benefit of recipient vaccination on days À1 and þ 50 in the absence of donor vaccination. This is important for marrow or blood stem cell grafting from unrelated donors and cord blood grafting, as in these settings donor vaccination is impractical or impossible. The reason for comparing the D N R À1,50,365 strategy with the D À20 R À1,50,365 strategy was to evaluate the added benefit of donor vaccination to the recipient pretransplant and early post transplant vaccination. This is important for the setting of marrow or blood stem cell transplantation from related donors. Firstly, if there was no added benefit, there would be no reason for exposing the donors to the potential side effects of the vaccines. Secondly, if there was a substantial added benefit, this might decrease the enthusiasm for using grafts depleted of T or B cells as the grafted T or B cells likely mediate the benefit.
The ability to transfer adoptively antibody immunity and the magnitude of antibody responses to vaccination after transplant depends on the chemical structure of the antigen and the number of encounters with the antigen before transplantation. 7, 8, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] To study a variety of antigens, we used S. pneumoniae capsular polysaccharides as a prototype of polysaccharide antigens, H. influenzae capsular polysaccharide conjugated to a carrier protein as a prototype of polysaccharide-protein conjugate antigens, tetanus toxoid as a prototype of protein recall antigens, and hepatitis B surface antigen (HBsAg) as a prototype of protein neo-antigens for most patients.
Methods

Study design
Recipients of transplants from HLA-matched-related donors and their donors were asked to participate in a randomized comparison of immunization against S. pneumoniae, H. influenzae, tetanus and hepatitis B of the recipient on days À1, 50 and 365 (D N R À1,50,365 ) vs the recipient on days À1, 50 and 365 post transplant plus the donor pretransplant (on arrival for pretransplant evaluation; the actual median day was À20, range À47 to À14) (D À20 R À1,50,365 ). Recipients of transplants from HLA-matched-related donors who did not participate in the randomized study but agreed to multiple research blood draws were immunized with the same vaccines per our standard practice on day 365 and not on day À1 or 50 (D N R 365 ) ( Table 1 ). The goal was to answer the primary question of the efficacy of donor vaccination pretransplant (D À20 R À1,50,365 vs D N R À1,50,365 ) in a randomized way, and the secondary question of the efficacy of recipient vaccination on days À1 and 50 (D N R À1,50,365 vs D N R 365 ) in a nonrandomized way. As a control antigen, polio vaccine was given to all patients on day 365. The study was approved by the Institutional Review Board and all patients signed informed consents.
Patients and donors
Of 116 patients accrued, 85 patients were analyzed -only those available for the day À1 and 50 immunizations and for the testing of antibody levels on or after day 80. The major reason for nonavailability was death or relapse by day 80, which occurred in 28 patients. The reason for our focusing on the days 80 to 365 interval is that specific antibody levels to recall antigens fall from recipient pretransplant levels substantially only after day 80, 15, 20, 21 and that during this interval a substantial rise of the antibody levels cannot be achieved by vaccination (without pretransplant vaccination). The demographic and clinical/immunological characteristics of the 85 patients are displayed in Table 2 . The D À20 R À1, 50, 365 and D N R À1,50,365 groups were balanced for all the characteristics (Table 2 , footnote a), suggesting that differences in antibody levels should be due to donor vaccination pretransplant. Likewise, the D N R À1, 50, 365 and D N R 365 groups were balanced for all the characteristics (Table 2 , footnote a), suggesting that differences in antibody levels should be due to recipient vaccination on days À1 and 50.
All the patients participated also in a randomized study of marrow vs filgrastim-mobilized blood stem cell grafting and have been reported by us. [22] [23] [24] Antibody immunity was unaffected by the type of graft, as the levels of total IgG were similar after marrow and blood stem cell transplantation, 23 the levels of antigen-specific antibodies were also similar, 24 and antibody responses to post transplant immunization with keyhole limpet hemocyanin and inactivated polio vaccine were also similar (Storek et al, unpublished) . None of the patients had a preceding hematopoietic cell transplant. All patients received graft-versus-host disease prophylaxis with methotrexate (days 1, 3, 6 and 11) plus cyclosporine (daily for 6 months). 25 Blood was drawn for the determination of specific antibody levels in the donors pretransplant (before donor vaccination) and at 1 month after vaccination, and in the patients pretransplant (before day À1 vaccination) and on approximately days 50 (before vaccination), 80, 180, 365 (before vaccination) and 395 (1 month after vaccination). The numbers of patients studied at each For all other characteristics, the significance was determined by w 2 test or, when appropriate, by Fisher's exact test. b Good risk: chronic myelogenous leukemia in first chronic or accelerated phase, acute leukemia in first remission, refractory anemia, myelofibrosis. Poor risk: chronic myelogenous leukemia in blast crisis, acute leukemia beyond first remission, refractory anemia with excess blasts, lymphoma, multiple myeloma. c All conditioning regimens were myeloablative. The most frequent chemotherapy only regimen was IV cyclophosphamide (120 mg/kg) with PO busulfan (approximately 16 mg/kg). The most frequent chemotherapy plus total body irradiation (TBI) regimen was cyclophosphamide (120 mg/kg) with fractionated TBI (12.0-13.2 Gy). Three patients from the 'TBI+chemotherapy' group received fractionated total marrow irradiation (9.0 Gy, similar to upper mantle and inverted Y) instead of TBI (one D N R 365 patient, one D N R À1,50,365 patient and one D À20 R À1,50,365 patient). d Typically treated with prednisone 1-2 mg/kg/day PO for 10-14 days with subsequent taper over 50 days. e Typically treated with prednisone (0.5-1.0 mg/kg every other day PO) plus cyclosporine (approximately 6 mg/kg every other day PO) for at least 9 months. f For chronic myelogenous leukemia, the detection of bcr/abl transcript by PCR in the absence of cytogenetic or hematologic relapse was not considered a relapse. As the goal of the study was to evaluate transplant-associated immune deficiency and not malignancy-associated immune deficiency, antibody levels of patients who relapsed post transplant were evaluated only before the diagnosis of relapse. g Typically, 200 mg/kg weekly before day 100, 500 mg/kg monthly after day 100 until preinfusion level of 400 mg/dl has been achieved. Antibody levels in sera obtained within 2 months after the administration of intravenous immunoglobulin were not evaluated.
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Vaccines
The following vaccines were used: Pnu-Immune (Wyeth/ Lederle, Philadelphia, PA, USA) containing the capsular polysaccharides of 23 common pneumococcal serotypes, 0.5 ml. IM; HibTITER (Wyeth/Lederle, Philadelphia, PA, USA) containing H. influenzae type b capsular polysaccharide conjugated to diphtheria CRM197 protein, 0.5 ml IM; Td (Wyeth/Lederle, Philadelphia, PA, USA) containing tetanus and diphtheria toxoids, 0.5 ml IM; and Recombivax HB (Merck, West Point, PA, USA) containing HBsAg, 1.0 ml IM (except for one 15-year-old patient who received 0.5 ml IM as per the manufacturer's recommendation). On day 365, all patients who were alive and in remission also received IPOL (Pasteur/Connaught, Swiftwater, PA, USA) containing formalin-inactivated poliovirus 1, 2 and 3, 0.5 ml s.c.
Antibody levels
Serum levels of IgG specific for tetanus toxoid, H. influenzae capsular polysaccharide or for a mixture of 23 common pneumococcal polysaccharide serotypes were determined by ELISA, using kits purchased from The Binding Site (Birmingham, UK). Levels of antibodies against HBsAg were determined by ELISA, using kits purchased from DiaSorin (Saluggia, Italy). Most patients and donors had undetectable anti-HBsAg pretransplant (Figure 1 ), suggesting that HBsAg represented a neoantigen for most patients and donors. One D N R À1,50,365 patient was a carrier of hepatitis B; he was excluded from the analysis of post transplant anti-HBsAg levels. Levels of antibodies against poliovirus 1 were determined by a virus binding inhibition assay as described. 26, 24 Levels of IgG against S. pneumoniae serotype 4, 6B, 9V, 14, 18C, 19F and 23F were determined using a flow cytometric (ImmunoArray) assay. 27 Briefly, all seven pneumococcal capsular polysaccharide serotypes (ATCC, Manassas, VA, USA) were covalently attached onto different microsphere sets (Luminex Corporation, Austin, TX, USA). The microsphere sets were then pooled to make up a microsphere mixture and incubated with serum samples diluted 1 : 400 with a 1% bovine serum albumin/ PBS-based sample diluent buffer. All unbound material was then washed away using a Tween-20/PBS-based wash buffer. The quantitation of bound antibodies was performed using a polyclonal anti-human IgG conjugated with phycoerythrin (PE) and the Luminex-100 flow cytometer. Microspheres carrying a specific pneumococcal serotype were characterized by unique spectral fluorescent emission signatures after 635 nm red laser excitation of varying proportions of embedded red and infrared fluorescent dyes. The amount of bound pneumococcal polysaccharide antibodies on each microsphere was measured by the orange fluorescence emission of PE-conjugated anti-human IgG antibodies excited with a 532 nm green laser. The amount of anti-pneumococcal polysaccharide antibody bound onto the microsphere was proportional to the measured amount of PE-conjugated anti-human IgG antibody. Using known standards (eight levels) that were calibrated against the US FDA Pneumococcal Reference Serum 89SF, standard curves for all seven serotypes were generated, and all unknown sample results were interpolated from these curves. For statistical evaluations, levels of S. pneumoniae, H. influenzae, tetanus and HBsAg antibodies below the lower detection limit (antibody concentration of the least concentrated standard) were assigned values equaling the lower detection limit divided by 2. Levels of antibodies above the upper detection limit were remeasured using 10 and 100 times higher serum dilutions. On the rare occasion when even with the 100 times higher serum dilution the reading was higher than the upper detection limit (antibody concentration of the most concentrated standard Â 100), the level was assigned a value equaling the upper detection limit multiplied by 2.
Tetanus lymphoproliferation assay
Cryopreserved density gradient (1.077 kg/l)-separated. mononuclear cells were suspended at 2 Â 10 6 cells/ml in RPMI with 10% human AB serum, glutamine (4 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml) and amphotericin B (250 ng/ml). The mononuclear cell suspension (100 ml) was dispensed into wells of 96 round-bottom plates. Tetanus toxoid (kind gift of Lederle Laboratories, Pearl River, NY, USA) was added to triplicate wells at a final concentration of 1.67 LFU/ml on day zero. The plates were incubated at 371C in a humidified 5% CO 2 atmosphere for 4 days. At 18-24 h before harvest, 3 H-thymidine (2 mCi) was added to each well. Cells were harvested using a semiautomated harvester, and counts per minute (cpm) were determined in a b scintillation counter. The mean cpm of cells exposed to the antigen minus the mean cpm of cells incubated with medium alone (D cpm) was calculated.
Statistics
Medians rather than means are given as the antibody levels and W cpm values were typically not normally distributed. Significance of differences between patient groups or donor groups at each time-point was tested by the MannWhitney-Wilcoxon rank sum test. Two-tailed P-values were used. To minimize the number of spurious findings due to multiple comparisons of antibody levels, the stringent significance level of 0.02 was used as the cutoff for declaring statistical significance.
Results
Effect of vaccination strategy on antibody levels
The effects of the donor vaccination on day À20 (determined by the comparison of patients randomized to D À20 R À1,50,365 vs D N R À1,50,365 strategy) and of the recipient vaccination on day À1 and 50 (determined by the nonrandomized comparison of D N R À1,50,365 vs D N R 365 patients) differred among the various antigens (Figure 1) . For H. influenzae and tetanus, the median IgG levels were higher in D À20 R À1,50,365 than D N R À1,50,365 patients at most post transplant time-points (statistically significant for H. influenzae on day 180 and for tetanus on day 50), suggesting that the donor vaccination was efficacious. The median IgG levels were higher in D N R À1,50,365 than D N R 365 patients at all post transplant time-points (statistically significant for both H. influenzae and tetanus on days 80 and 180), suggesting that the recipient vaccination on day À1 and 50 was efficacious. Of the 3 vaccination strategies, only the D À20 R À1,50,365 strategy was associated with median H. influenzae IgG levels higher than the presumed protective level (1 mg/l) 28 at all the post transplant timepoints. In contrast to H. influenzae and tetanus, S. pneumoniae IgG levels in all the three groups were similar, except on day 80. For HBsAg, the median antibody levels in all 3 groups were below the detection limit (arbitrarily assigned a value of 2.5 mIU/ml) both pretransplant and at all the post transplant time-points, precluding comparison among the groups. However, an advantage of the D À20 R À1,50,365 group over the other two groups was unlikely because the 90th percentiles of the anti-HBsAg levels (which were above the detection limit) were similar in all three groups; they were actually lower in the D À20 R À1,50,365 group than in the D N R 365 group on day 50, 80 and 180 (data not shown).
The differences in H. influenzae and tetanus IgG (D À20 R À1,50,365 4D N R À1,50,365 4D N R 365 ) did not appear to be attributable to differences in donor or recipient specific IgG levels pretransplant. There were no significant differences between the patient groups in the levels of recipient H. influenzae or tetanus IgG pretransplant or the levels of donor H. influenzae or tetanus IgG pretransplant (Figure 1 ). D À20 R À1,50,365 vs D N R À1,50,365 patients and D N R À1,50,365 vs D N R 365 patients were also balanced in the following factors that could theoretically affect the antibody levels: patient age, donor age, histocompatibility, CMV serostatus, splenectomy, conditioning, GVHD prophylaxis, incidence of grade 2-4 acute GVHD or clinical extensive chronic GVHD, relapse rate, the administration of glucocorticoids and post transplant B cell and CD4T cell counts (Table 2 , footnote a). Moreover, humoral immunity of the D N R 365 , D N R À1,50,365 and D À20 R À1,50,365 patients was similar as there were no significant differences in antibody levels against polio 1 (control antigen - Figure 1) .
The apparent lack of influence of the donor vaccination on day À20 and recipient vaccination on day À1 and 50 on post transplant IgG levels against S. pneumoniae could possibly be due to the fact that we determined total IgG against 23 serotypes. It is conceivable that IgG levels against certain serotypes were higher in D À20 R À1,50,365 patients compared to D N R À1,50,365 or D N R 365 patients. To evaluate this possibility, we determined days 365 and 395 levels of IgG against serotype 4, 6B, 9V, 14, 18C, 19F and 23F (Figure 2 (Figure 1 ). This suggested that the D À20 R À1,50,365 patients had the largest number of antigen-specific lymphocytes or the most functional antigen-specific lymphocytes (either antigenspecific helper T cells ready to proliferate and help B cells or antigen-specific B cells ready to proliferate and differentiate into plasma cells), and that the D N R 365 patients had the lowest number of or the least functional antigen-specific lymphocytes. To evaluate this hypothesis, in vitro lymphocyte proliferation upon stimulation with tetanus toxoid was measured on day 365 (before the day 365 vaccination). This assay measures the stimulation of tetanus-specific CD4T cells and B cells. 29, 30 As expected, the lymphocyte proliferation was significantly higher in D À20 R À1,50,365 patients than D N R À1,50,365 patients (P ¼ 0.03) or D N R 365 patients (Po0.001), and significantly higher in D N R À1,50,365 patients than D N R 365 patients (P ¼ 0.01) (Figure 3 ). Of interest, the lymphocyte proliferation in the D À20 R À1,50,365 patients was even higher than in the donors (Po0.001). Thus, the D À20 R À1,50,365 vaccination strategy resulted in a large number of or very functional antigen-specific CD4T cells or B cells.
Adverse events
Two patients developed a severe local reaction (possible infection) to day À1 vaccination during severe neutropenia. Both patients were from the D N R À1,50,365 group. Both patients were given tetanus þ diptheria vaccine into the right quadriceps muscle on day À1. The first patient developed right thigh swelling on day 11. Computer tomogram showed an area of hypodensity (suggesting inflammation) in the quadriceps muscle. Fluid aspirated from that site showed Gram positive rods (possibly Clostridia) that did not grow in culture. On day 12, the site was surgically explored. Inflamed tissue was excised, and histology showed necrotizing fasciitis with mild myositis. No microorganisms were seen and cultures were Magnetic resonance imaging showed a subcutaneous area of probable inflammation. Clindamycin was added to prophylactic antibiotics and the swelling improved. On day 7, clindamycin was discontinued. By day 9, the swelling worsened. Clindamycin was restarted, and the swelling abated. Culture of the vaccine (another vial from the same lot) was negative. These two cases suggest that unexpected side effects of licensed vaccines may occur in the peritransplant setting.
Discussion
The major findings of this study are that for H. influenzae (prototypal polysaccharide-protein conjugate antigen) and tetanus (prototypal protein recall antigen), specific antibody levels after transplant can be improved by vaccinating the recipient on days À1 and 50, and that the levels can be further improved by vaccinating the donor on day À20. This suggests that immunizing the recipient pretransplant and early post transplant is beneficial even if the donor cannot be vaccinated as in the setting of cord blood transplantation or unrelated marrow or blood stem cell transplantation. Moreover, it suggests that if in the setting of T-and B-cell-replete transplantation the donor can be vaccinated, it is beneficial to vaccinate also the donor. Disappointingly, even the D À20 R À1,50,365 strategy did not result in a substantial rise of antibodies for S. pneumoniae polysaccharides and for HBsAg (prototypal protein neoantigen). The lack of efficacy for pneumococcal capsular polysaccharides is particularly disturbing as S. pneumoniae causes significant morbidity and mortality. In the 1970s and early 1980s, 9-27% transplant survivors developed an infection due to S. pneumoniae and up to 8% died of pneumococcal infections. 31, 32 In the 1990s, only 3-6% transplant survivors developed a pneumococcal infection (Storek and Sullivan, unpublished; Kulkarni et al 33 ), probably as a result of chemoprophylaxis with sulfamethoxazole/trimethoprim or penicillin. The percentage may rise in the 2000s due to the rapid emergence of resistant pneumococci. 34, 35 Fortunately, vaccination of the donor pretransplant and the recipient pretransplant and early post transplant with the new heptavalent polysaccharide þ protein conjugate vaccine (Prevnar) appears to improve the post transplant antibody levels for the seven serotypes contained in the vaccine. 2 For the serotypes not contained in the heptavalent vaccine, the best prophylaxis continues to be antibiotic prophylaxis during the first year and immunization with the 23-valent polysaccharide vaccine at 1 year post transplant (see Figures 1 and 2 for the moderate efficacy of the 23-valent vaccine at 1 year post transplant).
Regarding protein neo-antigens, our inability to achieve detectable levels of antibodies against HBsAg in the D À20 R À1,50,365 patients contrasts with the study of Wimperis et al 10 describing detectable antibody levels to keyhole limpet hemocyanin (KLH) post transplant in all patients immunized with KLH pretransplant whose donors were immunized 3 weeks pretransplant. The discrepancy could be due to the relatively poor immunogenicity of HBsAg compared to KLH. In most healthy persons, anti-HBsAg levels become detectable (exceed the detection limit of 5 mIU/ml) only after two doses of hepatitis B vaccine, 36 whereas a marked rise in KLH antibodies occurs already after one dose of KLH. 37 Collectively, the donor vaccination at B3 weeks pretransplant with recipient vaccination both pretransplant and early post transplant may be efficacious for highly immunogenic protein neo-antigens like KLH or protein recall antigens like tetanus toxoid, but not for poorly immunogenic protein neo-antigens like HBsAg. Repetitive donor vaccination with a poorly immunogenic protein neo-antigen pretransplant (converting the neo-antigen to a recall antigen) may circumvent this problem. 38 The use of antibody levels as surrogates of protection against infection is a drawback of our study. This is because the infections for which we vaccinated are relatively rare. Only one patient in our study developed recurrent pneumococcal infections (D À20 R À1,50,365 patient) and one patient developed a H. influenzae infection (D N R À1,50,365 patient) in the first year after transplant (see Storek et al 23 for the follow-up for and definition of infections). For the same reason, the Centers for Disease Control recommendations are also based on antibody levels. 9 Up until recently only infections that are rare (H. influenzae) or unreported (tetanus, diphtheria, polio) after transplantation could have been possibly prevented by the D À20 R À1,50,365 vaccination strategy. This precluded a vaccination trial with the end point of the incidence of clinical infection, as extremely large numbers of patients would be required to document a benefit. However, with the advent of the pneumococcal heptavalent conjugate vaccine and the inactivated varicella vaccine and the documentation of their immunogenicity in transplant recipients, 7, 39 the time has come to compare the D À20 R À1,50,365 or a similar vaccination strategy with a standard management, in a trial using the S. pneumoniae and H. influenzae conjugate vaccines and the varicella inactivated vaccine. The trial should evaluate the end point of the incidence of clinical S. pneumoniae, H. influenzae and varicella virus infections. Given the potential toxicities of the D À20 R À1,50,365 vaccination (including vaccination site infections -see Results, last paragraph), the D À20 R À1, 50, 365 or similar strategy can be recommended for routine clinical use only if a favorable risk : benefit ratio is found in the proposed clinical trial.
Transfer of antigen-specific immunity was first documented by Lum and co-workers 16, [40] [41] [42] [43] Boosting of the transferred immunity by immunizing the donor within 1 month pretransplant and of the recipient within 1 week pretransplant was pioneered by Wimperis and co-workers [17] [18] [19] [44] [45] [46] [47] However, the patients in the boosting studies were usually followed for only several months. Here we show that the effect of the donor vaccination pretransplant and recipient vaccination peritransplant against a protein recall antigen or a polysaccharide-protein conjugate antigen appears to persist for at least 1 year.
The D À20 R À1,50,365 vaccination strategy may also be explored for tumor antigens. 47, 48 Data about antitumor effect of antibodies have been accumulating. High levels of antibodies against tumor-associated antigens in nontransplant patients have been associated with low tumor progression rates 49, 50 and the administration of antibodies against tumor-associated antigens has resulted in tumor remissions. Examples include trastuzumab/anti-her2neu for breast cancer, cetuximab/anti-EGFR for colon cancer, rituximab/anti-CD20 or anti-Ig idiotype for non-Hodgkin's lymphoma, and alemtuzumab/anti-CD52 for chronic lymphocytic leukemia (reviewed by White et al 51 ) . Moreover, the D À20 R À1,50,365 strategy may improve antitumor lymphocyte functions other than antibody production (eg, proliferation - Figure 3) .
In summary, donor vaccination pretransplant and recipient vaccination on days À1 and 50 are likely to be of no benefit when immunizing with a polysaccharide antigen or a poorly immunogenic protein neo-antigen. Donor vaccination pretransplant (around day À20) and/or recipient vaccination on days À1 and 50 lead to high antibody levels during the first year after transplant when immunizing with a polysaccharide-protein conjugate antigen, a protein recall antigen and, possibly, a highly immunogenic protein neo-antigen. However, given the uncertainty about adverse effect (see Results, last paragraph) and about whether increased antibody levels translate into fewer infections, we recommend vaccination of donors pretransplant and recipients peritransplant only in the setting of clinical trials. Outside of clinical trials, the Centers for Disease Control guidelines (currently recommending only post transplant vaccination) 9 should be followed.
